471820.KQ Cellromax Science Co., Ltd.

Healthcare Pharmaceutical Retailers KOSDAQ
3,995 KRW
Close of Nov 1, 2026
3,368 7,373
Market cap
KRW 43.9B
P/E
14.2x
P/B
0.94x
ROE
8.5%
Dividend yield
7.72%
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 471820.KQ undervalued?

Graham number
Price3,995
Graham value5,196
Discount23.1%

471820.KQ trades 23.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cellromax Science Co., Ltd. fundamental analysis

9 of 22 checks passed

ROE 0/2

Low return on equity (8.5%), below 10%.

ROA 1/1

Return on assets (7.9%) is above the industry median (-0.2%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (-21.8%) is above the industry median (-33.3%).

Revenue Growth 1/2

Revenue grew 1.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 180.4x against interest expense, well covered.

PE vs Market 0/1

PE (14.2x) is above the market median (11.3x).

PE vs Industry 0/1

PE (14.2x) is above the industry median (11.3x).

PBV 0/1

Price to book (0.9x) is above the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 13.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 2/2

Dividend yield (7.7%) is in the top 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

Payout ratio is 114.3%, above 90% of earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Cellromax Science Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cellromax Science Co., Ltd.

Cellromax Science Co., Ltd. focuses to merge with other companies. The company was founded in 2022 and is based in Seoul, South Korea.

Full company profile